Rani Therapeutics Holdings (RANI) Times Interest Earned (2020 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Times Interest Earned of -$3.44 for Q1 2026, up 73.03% year-over-year from -$1.99 in Q1 2025, and up 80.84% quarter-over-quarter from -$17.93 in Q4 2025.
Rani Therapeutics Holdings (RANI) Times Interest Earned (2020 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Times Interest Earned history runs 7 years deep, the most recent figure standing at -$3.44 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 73.03% year-over-year to -$3.44; the TTM figure through Mar 2026 stood at -$14.27 (up 10.69% YoY), while the FY2025 annual figure was -$0.48, up 95.43% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$3.44, up from -$17.93 in the prior quarter.
- The five-year high for Times Interest Earned was $6.16 in Q4 2024, with the low at -$28.47 in Q3 2022.
- The 5-year median for Times Interest Earned is -$11.07 (2025), against an average of -$10.46.
- The sharpest annual moves came in 2022 and 2024: Times Interest Earned sank 1068.49% in 2022, then soared 255.95% in 2024.
- Rani Therapeutics Holdings' Times Interest Earned stood at -$24.31 in 2022, then soared by 83.76% to -$3.95 in 2023, then jumped by 255.95% to $6.16 in 2024, then plunged by 391.17% to -$17.93 in 2025, then jumped by 80.84% to -$3.44 in 2026.
- Business Quant data shows RANI's Times Interest Earned at -$3.44 in Q1 2026, -$17.93 in Q4 2025, and -$1.52 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Rani Therapeutics Holdings | 163.98 Mn | 163.98 Mn | - | -1,103.50 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.18 |
| Mar 31, 2026 | -3.44 |
| Dec 31, 2025 | -17.93 |
| Sep 30, 2025 | -1.52 |
| Jun 30, 2025 | -11.07 |
| Mar 31, 2025 | -12.74 |
| Dec 31, 2024 | 6.16 |
| Sep 30, 2024 | -1.77 |
| Jun 30, 2024 | -9.10 |
| Mar 31, 2024 | -10.85 |
| Dec 31, 2023 | -3.95 |
| Sep 30, 2023 | -13.57 |
| Jun 30, 2023 | -14.38 |
| Mar 31, 2023 | -13.68 |
| Dec 31, 2022 | -24.31 |
| Sep 30, 2022 | -28.47 |
| Jun 30, 2022 | -14.69 |
| Mar 31, 2022 | -2.43 |
| Dec 31, 2021 | 13,362.00 |
| Sep 30, 2021 | -2.44 |